LONDON--Oxford Biomedica PLC (OXB.LN), a gene-based biopharmaceutical company, and its partner Sanofi (SNY) Tuesday announce a positive interim review of the RetinoStat(R) Phase I study in neovascular "wet" age-related macular degeneration, or AMD, and the StarGen(TM) Phase I/IIa study in Stargardt disease.
-Study was undertaken by the Data Safety Monitoring Board, or DSMB, an independent panel of specialists in the fields of ophthalmology, virology and vectorology.
-RetinoStat(R) open label, dose escalation Phase I study will enrol 18 patients with "wet" AMD and will evaluate three dose levels to assess safety and aspects of ocular physiology.
-StarGen(TM) open label, dose escalation Phase I/IIa study will enrol up to 28 patients and will evaluate three dose levels for safety, tolerability and aspects of biological activity;
-Further results from both studies expected in Q4.
-Shares at 0705 GMT up 6.09% at 2 pence valuing the company at 31.19 million pounds.
-Write to Ian Walker at firstname.lastname@example.org
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
August 08, 2012 03:22 ET (07:22 GMT)
Copyright (c) 2012 Dow Jones & Company, Inc.